San Antonio Breast Cancer Symposium (SABCS)

The combination of trastuzumab deruxtecan and pertuzumab could improve efficacy over trastuzumab deruxtecan alone for patients with HER2-positive metastatic breast cancer.

Zanidatamab and single agent chemotherapy may hold promise in a population of patients with previously treated HER2-positive breast cancer.

Tucatinib plus palbociclib and letrozole prolonged central nervous system progression-free survival for patients with hormone receptor–positive, HER2-positive breast cancer.

Premenopausal women with hormone receptor-positive, HER2-negative breast cancer saw a survival benefit when treated with adjuvant chemotherapy.

Black patients may have poorer outcomes during breast cancer treatment than White patients.

Data collected from 1400 global laboratories indicate that standard immunohistochemistry testing may not be the most effective method to identify patients with breast cancer with HER2-low disease.

Research presented at the 2021 San Antonio Breast Cancer Symposium highlighted survival improvements for postmenopausal women with hormone receptor–positive HER2-negative advanced breast cancer when treated with ribociclib plus letrozole over placebo.

Those with higher Oncotype DX scores may be more likely to complete the recommended 5 years of endocrine therapy for breast cancer.

Pooled efficacy and safety data confirm that patients who self-identify as Black or Hispanic can be safely treated with palbociclib plus endocrine therapy for hormone receptor–positive, HER2-negative advanced breast cancer.

Patients with early triple-negative breast cancer across prespecified subgroups who were given neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant single-agent pembrolizumab in a phase 3 trial saw an improvement in event-free survival.

Positive response data were seen when patients with advanced or metastatic triple-negative breast cancer were treated with datopotamab deruxtecan.

Results of a phase 3 trial presented at 2021 SABCS indicated that entinostat plus exemestane improved progression-free survival for Chinese patients with advanced hormone receptor–positive breast cancer vs placebo.

Patients with hormone receptor-positive, HER2-negative early breast cancer did not see a benefit when adjuvant palbociclib was added to standard endocrine therapy.

Patients with previously untreated, locally recurrent, inoperable, or metastatic triple-negative breast cancer derived a statistically significant survival benefit following treatment with pembrolizumab and chemotherapy.

A phase 3 trial analysis found that metformin does not improve invasive disease-free survival or overall survival rates for patients, regardless of hormone receptor status.

Fulvestrant plus palbociclib after aromatase inhibitor plus palbociclib led to improvements in progression-free survival for patients with hormone receptor–positive, HER2-negative metastatic breast cancer.

Elacestrant significantly improved progression-free survival in estrogen receptor–positive HER2-negative metastatic breast cancer.

A pooled analysis found that genomic alterations identified through multigene sequencing led to progression-free survival improvements over maintenance chemotherapy for HER2-negative metastatic breast cancer.

Black women with breast cancer had a 3.5-fold higher rate of lymphedema over 24 months compared with White women.

Treatment with tamoxifen for primary breast cancer may result in increased risk of developing subsequent uterine cancer by activating the PI3K pathway.

Imaging mass cytometry at the single-cell level showed potential as an immunotherapy response prediction tool in early triple-negative breast cancer.

“We’re hearing about other antibody-drug conjugates, other agents in hormone receptor–positive metastatic disease, and the next generation of drugs that we’ll be using to treat our patients.”

Investigators aimed to evaluate additional end points from the phase 3 RxPONDER trial in women with hormone receptor–positive, HER2-negative, lymph node–positive breast cancer.

In this trial, investigators launched RxPONDER, in which 5015 patients with a recurrence score between 0 and 25 were randomized to endocrine therapy alone or chemotherapy followed by endocrine therapy.

A recent study sought to evaluate the 21-gene Oncotype Dx Recurrence Score in nonmetastatic HR-positive, HER2-negative breast cancer.

The breast medical oncologist and researcher discussed how the addition of chemotherapy to endocrine therapy showed clinical benefit in premenopausal, lymph node-positive, HR-positive, HER2-negative breast cancer.

Research presented at the 2020 SABCS found providers planned to use neoadjuvant endocrine therapy for as little as possible until surgery was available for patients with estrogen receptor positive breast cancer.

This study revealed that reliability, or patient interpretation of telemedicine as a substitute for in-person visits, of the platform was of the greatest concern to all patients.

The GP2/GM-CSF combination demonstrated a 100% disease-free survival at 5 years for patients with HER2/neu 3–positive disease who received adjuvant trastuzumab.

For women with heavily pretreated, postmenopausal advanced or metastatic estrogen receptor (ER)–positive breast cancer, amcenestrant prompted antitumor activity.